Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LM-299 + Sacituzumab tirumotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LM-299 | LM 299|LM299|MK2010|MK-2010|MK 2010 | PD-L1/PD-1 antibody 138 VEGF Antibody 17 | LM-299 is a bispecific antibody targeting PDCD1 (PD-1) and VEGF, which potentially inhibits tumor growth (Cancer Res (2026) 86 (8_Supplement): CT057; NCT06650566). | |
| Sacituzumab tirumotecan | SKB 264|SKB-264|ADC SKB264|MK-2870|MK 2870|MK2870|SKB264 | TROP2 Antibody 20 | Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (PMID: 41276258, Cancer Res (2024) 84 (7_Supplement): CT038). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07785609 | Phase II | LM-299 + Sacituzumab tirumotecan | A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) | Recruiting | USA | CHE | 1 |